Date: 2013-12-06
Type of information: Licensing agreement
Compound: microsatellite instability (MSI) biomarkers
Company: Biocartis (Belgium) VIB (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: Microsatellite instability (MSI) is one of the premier molecular markers in CRC but is also important in ovarian, endometrial and gastric cancers. MSI evolves as a result of inactivation of the DNA mismatch repair (MMR) system and can be found in approximately 15% of all CRCs.
Disease: several cancers including colorectal cancer and ovarian cancer
Details: * On December 6, 2013, Biocartis and VIB have announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC). This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis’ molecular diagnostics platform Idylla™. Biocartis develops the innovative user-friendly diagnostic platform Idylla™1, for the molecular analysis of clinical samples. Biocartis also develops a wide range of clinically relevant tests for various diagnostic areas primarily in the field of oncology. For the development of a new assay for microsatellite instability, Biocartis joins forces with the world-renowned research institute VIB. As a result of the license agreement with VIB, Biocartis will develop a new CRC assay for MSI biomarker detection.
Financial terms:
Latest news:
